Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Empagliflozin”

444 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 444 results

Testing effectiveness (Phase 2)Study completedNCT05084235
What this trial is testing

The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure

Who this might be right for
Heart FailureObesity
Jacob Moller 191
Testing effectiveness (Phase 2)Study completedNCT01193218
What this trial is testing

Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 547
Early research (Phase 1)Study completedNCT07039890
What this trial is testing

To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions.

Who this might be right for
Type 2 Diabetes Mellitus (T2DM)
Humanis Saglık Anonim Sirketi 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT06342141
What this trial is testing

Empagliflozin for No-reflow Phenomenon in PCI for STEMI

Who this might be right for
STEMINo-Reflow Phenomenon
Instituto Nacional de Cardiologia Ignacio Chavez 162
Post-approval studies (Phase 4)UnknownNCT05942963
What this trial is testing

Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD

Who this might be right for
Non-Alcoholic Fatty Liver DiseaseType2diabetes
Jinnah Postgraduate Medical Centre 240
Post-approval studies (Phase 4)Study completedNCT03932721
What this trial is testing

EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial

Who this might be right for
Dyslipidemia Associated With Type II Diabetes MellitusDiabetes Mellitus, Type 2Hypertension Arterial
University of Campinas, Brazil 110
Not applicableStudy completedNCT06350903
What this trial is testing

Suppression With Empagliflozin as an Alternative To High-Fat Low-Carbohydrate Diet for Myocardial F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Imaging

Who this might be right for
Myocardial Suppression
Matthieu Pelletier-Galarneau, MD MSc 16
Early research (Phase 1)Study completedNCT05681273
What this trial is testing

Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.

Who this might be right for
T2DM
Chipscreen Biosciences, Ltd. 48
Large-scale testing (Phase 3)Study completedNCT01210001
What this trial is testing

Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 499
Not applicableStudy completedNCT06313008
What this trial is testing

Empagliflozin Versus Vildagliptin in CAD Patients With T2DM

Who this might be right for
Coronary Artery DiseaseType 2 Diabetes
Damanhour University 120
Early research (Phase 1)Study completedNCT02815644
What this trial is testing

Empa/Lina FDC Food Effect Study (Japan)

Who this might be right for
Healthy
Boehringer Ingelheim 22
Testing effectiveness (Phase 2)Study completedNCT01969747
What this trial is testing

Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days

Who this might be right for
Diabetes Mellitus, Type 1
Boehringer Ingelheim 75
Large-scale testing (Phase 3)Looking for participantsNCT07093476
What this trial is testing

Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

Who this might be right for
T2DMDiabete Type 2DM
Celltrion 171
Not applicableStudy completedNCT02864914
What this trial is testing

Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 333,580
Post-approval studies (Phase 4)UnknownNCT05778084
What this trial is testing

Effect of Empagliflozin on NT-Pro Brain Natriuretic Peptide in Heart Failure Patients With Reduced Ejection Fraction

Who this might be right for
Heart Failure With Reduced Ejection Fraction
Alexandria University 60
Early research (Phase 1)Study completedNCT02182453
What this trial is testing

Single Rising Oral Doses of BI 10773 in Healthy Male Volunteers

Who this might be right for
Healthy
Boehringer Ingelheim 48
Post-approval studies (Phase 4)Study completedNCT02589639
What this trial is testing

Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 269
Large-scale testing (Phase 3)Study completedNCT04157751
What this trial is testing

Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

Who this might be right for
Heart Failure
Boehringer Ingelheim 530
Not applicableStudy completedNCT06453577
What this trial is testing

Pharmacokinetics of Bisoprolol and SGLT2i in Acutely Decompensated Heart Failure

Who this might be right for
Acute Decompensated Heart Failure
Universität des Saarlandes 33
Testing effectiveness (Phase 2)Study completedNCT05493371
What this trial is testing

Empagliflozin in Pulmonary Arterial Hypertension

Who this might be right for
Idiopathic Pulmonary Arterial Hypertension
Amsterdam UMC, location VUmc 8
Next Page